Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when XENE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsXenon Pharmaceuticals reports Q1 2026 financial results
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
medium
Xenon announced first quarter 2026 financial results through a press release on May 7, 2026. The 8-K filing references the announcement but does not include actual financial figures or performance metrics.
Item 2.02 verify on EDGAR → -
low
The company disclosed its investor communication channels, including its website, social media accounts (X, LinkedIn, Facebook), and SEC filings as platforms for material information dissemination.
Item 7.01 verify on EDGAR →
Summary
Xenon Pharmaceuticals filed an 8-K to announce its first quarter 2026 financial results, though the filing itself contains no actual financial data or performance metrics. The company issued a press release on May 7, 2026, which was attached as an exhibit but not detailed in the filing body. This is a routine quarterly earnings announcement filing.
For retail investors, the key takeaway is that Q1 results have been released, but you'll need to review the actual press release or earnings materials to understand the company's financial performance. The filing also includes standard Regulation FD language about where Xenon communicates material information, reminding investors to monitor multiple channels including the company's investor relations website and social media accounts. Watch for any follow-up analyst commentary or management guidance that typically accompanies quarterly results.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (https://www.xenon-pharma.com), its investor relations website (https://investor.xenon-pharma.com), and its news site (https://investor.xenon-pharma.com/news-releases). The Company uses these channels, as well as social media, including its X (formerly known as Twitter) account (@XenonPharma), LinkedIn account (https://www.linkedin.com/company/xenonpharma/), and Facebook page (https://www.facebook.com/xenonpharma), to communicate with investors and the public about the Company, its product candidates, and other matters.
This is a procedural Regulation FD disclosure listing the various channels through which Xenon Pharmaceuticals disseminates material information to investors and the public. The company is notifying stakeholders that material information may be released through its websites, social media accounts, SEC filings, press releases, and conference calls.
Event · Item 9.01 — Financial Statements and Exhibits
Xenon Pharmaceuticals filed an 8-K to furnish a press release dated May 7, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release issued by Xenon Pharmaceuticals Inc. dated May 7, 2026.
The company furnished a press release dated May 7, 2026 via Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure cannot be determined from this filing alone. This is a procedural filing under Item 9.01 to attach an exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify